Pharmacodynamic modeling of β-lactam antibiotics for the empiric treatment of secondary peritonitis: A report from the OPTAMA program

Surgical Infections

Volumn 6, Issue 3, 2005, Pages 297-304

  Kotapati, Srividya ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CILASTATIN; CILASTATIN PLUS IMIPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL PERITONITIS; BACTERICIDAL ACTIVITY; DRUG CHOICE; DRUG EFFICACY; DRUG EXPOSURE; ENTEROBACTER; ESCHERICHIA COLI; HUMAN; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MODEL; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROTEUS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CILASTATIN; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PENICILLANIC ACID; PERITONITIS; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 27844553296     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2005.6.297     Document Type: Article

References (28)

1. Barie PS. Serious intra-abdominal infections. Curr Opin Crit Care 2001;7:263-267.
2. McClean KL, Sheehan GJ, Harding GKM. Intra-abdominal infection: A review. Clin Infect Dis 1994; 19:100-116.
3. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med 2003;31:2228-2237.
4. Cattan P, Yin DD, Sarfati E, et al. Cost of care for in-patients with community-acquired intra-abdominal infections. Eur J Clin Microb and Infect Dis 2002;21:787-793.
5. Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections: A review on randomised clinical trials. Eur J Med Research 2001;6:277-291.
6. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474.
7. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-2751.
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
9. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998;27:10-22.
10. Mattoes HM, Kuti JL, Drusano GL, et al. Optimizing antimicrobial pharmacodynamics: Dosage strategies for meropenem. Clin Ther 2004;26:1187-1198.
11. Bradley JS, Dudley MA, Drusano GL. Predicting efficacy of antibiotics with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003; 22:982-992.
12. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002. Antimicrob Agents Chemother 2004;48:2464-2470.
13. Kiffer CRV, Mencles C, Kuti JL, et al. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program: The OPTAMA Program, South America 2002. Diag Microbiol Infect Dis 2004;49:109-116.
14. Gibaldi M. Introduction to pharmacokinetics. In Gibaldi M, ed. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia: Lea & Febiger, 1984: 1-16.
15. Dreetz M, Hamacher J, Eller J, et al. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother 1996;40:105-109.
16. Primaxin (imipenem-cilastatin) package insert. West Point, PA: Merck and Co, Inc: 1999.
17. Merrem (meropenem) package insert. Wilmington, DE: Astra-Zeneca Pharmaceuticals LP: 2001.
18. Occipinti DJ, Pendland SL, Schoonover LL, et al. Pharmacokinetics and pharmacodynamics of two multiple dose piperacillin-tazobactam regimens. Antimicrob Agents Chemother 1997;41:2511-2517.
19. Zosyn (piperacillin/tazobactam) package insert. Collegeville, PA: Wyeth Pharmaceuticals: 2003.
20. Montravers P, Andremont A, Massias L, et al. Investigation of the potential role of Enterococccus faecalis in the pathopysiology of experimental peritonitis. J Infect Dis 1994;169:821-830.
21. NCCLS (National Committee for Clinical Laboratory Standards). Performance Standards for Antimicrobial Susceptibility Testing: eleventh informational supplement M100-S11. Wayne, PA: NCCLS, 2002.
22. Wittmann DH, Schein M, Condon RE. Management of secondary peritonitis. Ann Surg 1996;224:10-18.
23. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793-2797.
24. Kuti JL, Dandekar PK, Nightingale CH et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003;43:1116-1123.
25. Kuti JL, Horowitz S, Nightingale CH, Nicolau P. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. Pharmacotherapy 2005; 25:935-941.
26. Burnett RJ, Haverstock DC, Dellinger EP, et al. Definition of the role of Enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 1995;118:716-723.
27. Karlowsky JA, Draghi DC, Jones ME, et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003;47:1681-1688.
28. Kuti JL, Nightingale CH, Quintiliani R, et al. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis 2002;44:51-57.